1. Home
  2. LYRA vs HUBC Comparison

LYRA vs HUBC Comparison

Compare LYRA & HUBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYRA
  • HUBC
  • Stock Information
  • Founded
  • LYRA 2005
  • HUBC 2017
  • Country
  • LYRA United States
  • HUBC Israel
  • Employees
  • LYRA N/A
  • HUBC N/A
  • Industry
  • LYRA Medical/Dental Instruments
  • HUBC
  • Sector
  • LYRA Health Care
  • HUBC
  • Exchange
  • LYRA Nasdaq
  • HUBC Nasdaq
  • Market Cap
  • LYRA 18.0M
  • HUBC 16.4M
  • IPO Year
  • LYRA 2020
  • HUBC N/A
  • Fundamental
  • Price
  • LYRA $0.17
  • HUBC $0.55
  • Analyst Decision
  • LYRA Buy
  • HUBC
  • Analyst Count
  • LYRA 5
  • HUBC 0
  • Target Price
  • LYRA $4.50
  • HUBC N/A
  • AVG Volume (30 Days)
  • LYRA 2.2M
  • HUBC 473.1K
  • Earning Date
  • LYRA 11-12-2024
  • HUBC 12-13-2024
  • Dividend Yield
  • LYRA N/A
  • HUBC N/A
  • EPS Growth
  • LYRA N/A
  • HUBC N/A
  • EPS
  • LYRA N/A
  • HUBC N/A
  • Revenue
  • LYRA $1,471,000.00
  • HUBC $42,657,000.00
  • Revenue This Year
  • LYRA $13.99
  • HUBC N/A
  • Revenue Next Year
  • LYRA N/A
  • HUBC N/A
  • P/E Ratio
  • LYRA N/A
  • HUBC N/A
  • Revenue Growth
  • LYRA 3.37
  • HUBC N/A
  • 52 Week Low
  • LYRA $0.17
  • HUBC $0.43
  • 52 Week High
  • LYRA $6.79
  • HUBC $4.50
  • Technical
  • Relative Strength Index (RSI)
  • LYRA 30.70
  • HUBC 54.42
  • Support Level
  • LYRA $0.26
  • HUBC $0.51
  • Resistance Level
  • LYRA $0.28
  • HUBC $0.61
  • Average True Range (ATR)
  • LYRA 0.02
  • HUBC 0.05
  • MACD
  • LYRA -0.01
  • HUBC 0.01
  • Stochastic Oscillator
  • LYRA 1.69
  • HUBC 65.65

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About HUBC Hub Cyber Security Ltd.

Hub Cyber Security Ltd is engaged in the development of cyber products, software, quality systems, reliability, and risk management. It operates in several countries and provides cybersecurity computing appliances as well as a wide range of cybersecurity professional services. The company has two operating segments: the Product and Technology Segment, and the Professional Services Segment. The majority of its revenue comes from the professional services segment, which provides data and cybersecurity, system security and reliability solutions, as well as related services such as consulting, planning, training, integration, and ongoing servicing of cybersecurity, risk management, system quality, reliability, and security projects, including fully managed corporate cybersecurity services.

Share on Social Networks: